SCHEMBL23005242

SCHEMBL23005242

CC(C)(C)OC(=O)Nc1cnc(N(C=O)[C@@H](CCC(=O)O)C(=O)O)c(F)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 11/20 0.38
SYK P43405 1/20 0.34
P2RX3 P56373 1/20 0.33
FPR2 P25090 2/20 0.33
MTHFD1 P11586 1/20 0.33
MTHFD2 P13995 1/20 0.33
HDAC4 P56524 2/20 0.32
HDAC1 Q13547 2/20 0.32
AR P10275 1/20 0.32
HDAC3 O15379 1/20 0.31
HDAC7 Q8WUI4 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC10 Q969S8 1/20 0.31
HDAC11 Q96DB2 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
HDAC9 Q9UKV0 1/20 0.31
HDAC5 Q9UQL6 1/20 0.31
KCNQ4 P56696 1/20 0.31
KCNQ5 Q9NR82 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23005174 0.82 FPR2 (0.38) FPR2MTHFD1MTHFD2HDAC1HDAC2
SCHEMBL23005127 0.79 MAPT (0.38)
SCHEMBL23005211 0.76 MTHFD1 (0.31) FPR2MTHFD1MTHFD2
SCHEMBL23005246 0.74 FPR2 (0.56) RORCFPR2MTHFD1MTHFD2
SCHEMBL23005243 0.74 FPR2 (0.56) RORCFPR2MTHFD1MTHFD2
SCHEMBL21494693 0.73 FPR2 (0.64) FPR2MTHFD1MTHFD2
SCHEMBL21494656 0.73 FPR2 (0.65) FPR2MTHFD1MTHFD2
SCHEMBL23005244 0.73 FPR2 (0.38) FPR2MTHFD1MTHFD2
SCHEMBL23005141 0.72 FPR2 (0.40) FPR2MTHFD1MTHFD2
SCHEMBL23005169 0.71 FPR2 (0.39) RORCFPR2MTHFD1MTHFD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3781554-B1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) 2023-06-28 EP disclosed
US-20230110478-A1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) 2023-04-13 US disclosed
US-20210052587-A1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY MEDICINSK FORSKNING (SE) 2021-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230110478-A1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY IL2, THPO, IL6 RORC 242/4885SYK 449/4885P2RX3 1619/4885
US-20210052587-A1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY IL2, THPO, IL6 RORC 233/4885SYK 493/4885P2RX3 1520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.